Saturday, November 08, 2025




In Detail Full day, Saturday, November 08, 2025, Timezone: America/Chicago


<![CDATA[Younger Age at Glomerular Disease Diagnosis Linked to Greater Lifetime Risk Despite Similar Progression Rates]]> / HCP Live

hcplive -

#healthcare #publichealth

4 months / hcplive

4 months / hcplive


Saturday, November 8, 2025, 8:21 pm / permalink 15810 / 3 stories in 4 months


Pfizer poised to buy Metsera in $10 bn deal after bidding war / Medical Express

medicalxpress - Pfizer was poised to seal a takeover of Metsera on Saturday after its improved offer won over the biotechnology startup's board and Danish challenger Novo Nordisk called a halt to a back-and-forth bidding war.

#obesity #healthcare #pharmaceuticals #novonordisk #weightloss #pfizer #biotech #mergersandacquisitions #corporatetakeover #drugdevelopment


Saturday, November 8, 2025, 3:21 pm / permalink 15805 / 2 stories in 4 months


Intensive blood pressure lowering could benefit almost all adults with hypertensive chronic kidney disease / Medical Express

medicalxpress - An analysis of the Systolic Blood Pressure Intervention Trial (SPRINT) indicates that nearly all adults with chronic kidney disease (CKD) would have benefits that outweigh the harm from a systolic blood pressure target of

#healthcare #publichealth

4 months / hcplive


Saturday, November 8, 2025, 2:22 pm / permalink 15802 / 2 stories in 4 months


#AHA25: Amgen’s cholesterol drug cuts first-time cardiovascular events by a quarter / Endpoints

Elizabeth Cairns / endpoints - Amgen on Saturday said its cholesterol-lowering drug Repatha cut cardiovascular events by 25% when added on top of standard therapy in high-risk patients who have never had a heart attack or stroke. Repatha is already ...

#healthcare #pharmaceuticals #publichealth

4 months / hcplive

4 months / hcplive

4 months / hcplive

4 months / hcplive

4 months / hcplive


Saturday, November 8, 2025, 9:21 am / permalink 15793 / 13 stories in 4 months


FDA approves J&J’s Darzalex for smoldering multiple myeloma / Endpoints

Lei Lei Wu / endpoints - The FDA on Thursday approved Johnson & Johnson’s Darzalex injection for high-risk smoldering multiple myeloma, a condition in which people have abnormal cells that could turn into myeloma but don’t have ...

#healthcare #pharmaceuticals #publichealth

4 months / targetedonc


Saturday, November 8, 2025, 12:21 am / permalink 15786 / 3 stories in 4 months


CMS unveils new Medicaid drug payment model / Endpoints

Max Bayer / endpoints - CMS plans to launch a new drug payment model for state Medicaid programs, the first of potentially multiple pricing models under President Donald Trump's "most favored nation" push that the pharma industry has been closely ...

#healthcare #pharmaceuticals #drugpricing #publichealth #governmentpolicy


Saturday, November 8, 2025, 12:21 am / permalink 15785 / 3 stories in 4 months


Patient in Intellia CRISPR trial dies after being hospitalized with liver injury / Endpoints

Ryan Cross / endpoints - A man in his early 80s who was recently hospitalized with liver injury, a few weeks after receiving an experimental gene editing therapy, died on Wednesday ...

#healthcare #pharmaceuticals #publichealth


Saturday, November 8, 2025, 12:21 am / permalink 15784 / 2 stories in 4 months


DNA pioneer James Watson dies at 97 / BBC

bbc - The Nobel Prize winner felt ostracised by the scientific community over his comments on race and intelligence.

#none


Saturday, November 8, 2025, 12:21 am / permalink 15783 / 3 stories in 4 months


StackHealth Time Machine




Outgoing Stories


HIMSS 2026 pushes real‑time data, cloud and interoperability playbook 14 stories in 16.5 hours

Neoadjuvant GOLP improves event‑free survival in high‑risk intrahepatic cholangiocarcinoma 3 stories in 17.5 hours

Vitamin D trial shows reduced long‑COVID risk but no severity benefit 2 stories in 19.5 hours

Atezolizumab added to chemoradiation fails to improve limited‑stage SCLC survival 4 stories in 20.5 hours

FDA approves leucovorin for rare folate disorder despite autism hype 4 stories in 32.5 hours

HORMAD1 emerges as a potential target in triple‑negative breast cancer 4 stories in 45.5 hours

Alfasigma pays $300M to GSK for linerixibat rights, expanding liver-disease portfolio 2 stories in 48.5 hours

Roche’s hoped‑for breast cancer pill fails crucial first‑line trial 5 stories in 49.5 hours

Novo Nordisk and Hims bury the hatchet and carve a deal 3 stories in 54.5 hours

AI improves UK breast-screening detection by about 10% 5 stories in 54.5 hours


More StackHealth


Bluesky:



NorthFeed Inc.

Disclaimer: The information provided on this website is intended for general informational purposes only. While we strive for accuracy, we do not guarantee the completeness or reliability of the content. Users are encouraged to verify all details independently. We accept no liability for errors, omissions, or any decisions made based on this information.